Articles from Osmind

Osmind, the platform powering the largest network of interventional psychiatry practices, today launched Osmind Intelligence, AI woven into the Osmind platform and shaped by experience supporting more than 1,000 psychiatry practices and the 1 million treatments they’ve delivered. Osmind Intelligence helps run practice operations across clinical and administrative work: it surfaces patients who may benefit from further evaluation, drafts clinical notes, suggests billing codes, and automates compliance workflows.

Osmind, the platform powering the largest network of independent psychiatry practices, and CareNet GPO, a group purchasing organization focused on psychiatry and behavioral health, today announced an exclusive partnership that gives independent practices the purchasing power and operational support to offer innovative psychiatric treatments sustainably—reducing drug costs and simplifying the workflows required to deliver them.

Bendable Therapy and Osmind will unveil the first real-world evidence study of legal psilocybin services in the United States, advancing scientific insights into safety and effectiveness of psychedelic medicine. These preliminary findings, which will be presented at Psych Congress 2025, represents the first systematic collection and analysis of outcomes data from Oregon's supervised psilocybin program under state Measure 109. The study fills a critical evidence gap, especially as multiple groups advance psychedelics programs towards FDA approval and medical adoption.

Osmind, the leading partner for forward-thinking psychiatry practices, today announced strategic appointments to its executive team, naming Adrian Vera as chief technology officer (CTO), Kelsey Friedman as vice president of operations, and Sabas Rodriguez as vice president of growth. These appointments address the administrative burden that causes psychiatric practices to struggle financially and fail to offer innovative treatments.

Today Osmind announced two new partnerships with Enthea and First Tracks Health to expand access to breakthrough treatments.

Today, Osmind, the leading psychiatric treatment and research platform, announced an innovative collaboration with the American Psychiatric Association (APA) to improve the adoption of measurement-based care (MBC) and precision treatment in psychiatry. This collaboration between Osmind and APA’s PsychPRO registry intends to broaden access to personalized care, improve patient outcomes, generate robust real-world evidence (RWE) and accelerate psychiatry’s evolution to precision medicine. PsychPRO registry is a clinical data registry that enables the collection and analysis of clinical data to advance quality improvement efforts and accelerate research for the psychiatric community.

Osmind, the public benefit corporation helping clinicians and researchers advance life-saving mental health treatment, today announced Osmind Claims, which introduces new billing capabilities purpose-built to simplify insurance reimbursement for psychiatric treatment, enabling greater access to insurance-supported mental health care.

Osmind, the public benefit corporation helping clinicians and researchers advance life-saving mental health treatment, today announced the results of a new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy (KIT). Developed in collaboration with a team of clinicians and published in the Journal of Affective Disorders, the results demonstrated significant patient improvement for depression, anxiety and suicidal ideation (SI).

Please replace the release dated September 15, 2022 with the following corrected version due to multiple revisions.

Osmind, the public benefit corporation helping clinicians and researchers advance new life-saving mental health treatments, today announced a $40 million Series B investment led by DFJ Growth. The Series B round brings the total amount of funding for Osmind to $57 million since the company’s founding in 2020. Justin Kao, partner at DFJ Growth, and the co-founder of Helix, will join the Osmind Board of Directors.

Osmind, a healthcare technology company and Public Benefit Corporation (PBC) dedicated to empowering clinicians and researchers to bring innovative mental health treatments to those who need it most, today announced the publication of a pivotal peer-reviewed article on real-world ketamine intravenous therapy (KIT). The study, conducted with leading physician-scientists at Stanford University School of Medicine, was published in the Journal of Affective Disorders. It is the largest published analysis of KIT outcomes in community care settings to date.

Osmind, the healthcare technology company and Public Benefit Corporation that is building the first digital infrastructure for neuropsychiatry and provides the #1 Electronic Health Record (EHR) software for innovative mental health practices, announced today that it has added new members to its leadership and Scientific Advisory Board to build on the momentum of its $15M series A funding.

Osmind, a healthcare technology company building the first digital infrastructure for neuropsychiatry, closed $15 million in Series A funding to further develop and expand its electronic health record (EHR) and research platform. The financing was led by Future Ventures, joined by existing investor General Catalyst and new investors Tiger Global, Offline Ventures, and Yahoo! co-founder Jerry Yang's AME Cloud Ventures.

Osmind, the leading ketamine, psychiatry, and treatment-resistant mental health electronic health record (EHR) software provider, has established a strategic partnership with Practolytics, a provider of revenue cycle management services with a focus on Spravato, ketamine, and general psychiatry headquartered in Columbia, SC.